Toward the use of nanopore RNA sequencing technologies in the clinic: challenges and opportunities
Nucleic Acids Research · 2025
DOI: 10.1093/nar/gkaf128 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nucleic Acids Research, 2025. Verfasst von Xanthi-Lida Katopodi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Dr. Aiguader 88, Barcelona 08003, Spain. Hauptthemen laut MEDLINE: Nanopore Sequencing, Sequence Analysis, RNA, RNA. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Union's Horizon Europe, AECC Foundation, European Union’s Horizon Europe.
Abstract (Originalsprache)
RNA molecules have garnered increased attention as potential clinical biomarkers in recent years. While short-read sequencing and quantitative polymerase chain reaction have been the primary methods for quantifying RNA abundance, they typically fail to capture critical post-transcriptional regulatory elements, such as RNA modifications, which are often dysregulated in disease contexts. A promising cutting-edge technique sequencing method that addresses this gap is direct RNA sequencing, offered by Oxford Nanopore Technologies, which can simultaneously capture both RNA abundance and modification information. The rapid advancements in this platform, along with growing evidence of dysregulated RNA species in biofluids, presents a compelling clinical opportunity. In this review, we discuss the challenges and the emerging opportunities for the adoption of nanopore RNA sequencing technologies in the clinic, highlighting their potential to revolutionize personalized medicine and disease monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Dr. Aiguader 88, Barcelona 08003, Spain.
- Universitat Pompeu Fabra (UPF), Barcelona, Spain.
- ICREA, Pg. Lluís Companys 23, Barcelona 08010, Spain.
ORCID-Profile: Xanthi-Lida Katopodi, Oguzhan Begik, Eva Maria Novoa
Förderung
- European Union's Horizon Europe
- AECC Foundation
- European Union’s Horizon Europe
Zitieren
APA
Katopodi, X. L., Begik, O., & Novoa, E. M. (2025). Toward the use of nanopore RNA sequencing technologies in the clinic: challenges and opportunities. Nucleic Acids Research. https://doi.org/10.1093/nar/gkaf128
Vancouver
Katopodi XL, Begik O, Novoa EM. Toward the use of nanopore RNA sequencing technologies in the clinic: challenges and opportunities. Nucleic Acids Research. 2025. doi:10.1093/nar/gkaf128
BibTeX
@article{Katopodi2025,
author = {Katopodi, Xanthi-Lida and Begik, Oguzhan and Novoa, Eva Maria},
title = {Toward the use of nanopore RNA sequencing technologies in the clinic: challenges and opportunities},
journal = {Nucleic Acids Research},
year = {2025},
doi = {10.1093/nar/gkaf128}
}
EUVIMED